Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
Article 2010 en
Authors
WJ
W. P. T. James
IC
Ian D. Caterson
WC
Walmir Coutinho
Abstract
1 min read
Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)
Bengt Fellström, Alan G. Jardine, Roland E. Schmieder, Hallvard Holdaas, Kym M. Bannister, Jaap J. Beutler, Dong‐Wan Chae, Alejandro Chevaile, Stuart M. Cobbe, Carola Grönhagen‐Riska, José J. De Lima, R. Lins, Gert Mayer, Alan W. McMahon, Hans‐Henrik Parving, Giuseppe Remuzzi, Ola Samuelsson, S. Sonkodi, Gültekin Süleymanlar, Dimitrios Tsakiris, Vladimı́r Tesař, Vasil Todorov, Andrzej Więcek, Rudolf P. Wüthrich, Mattis Gottlow, Eva Johnsson, Faı̈ez Zannad
Jens Jakob Thune, James Signorovitch, Lars Køber, Eric J. Velazquez, John J.V. McMurray, Robert M. Califf, Aldo Maggioni, Jean L. Rouleau, Jonathan G. Howlett, Steven L. Zelenkofske, Marc A. Pfeffer, Scott D. Solomon
Lars Sjöström, Kristina Narbro, C. David Sjöström, Kristjan Karason, Bo Larsson, Hans Wedel, Theodore C. Lystig, Marianne Sullivan, Claude Bouchard, Björn Carlsson, Calle Bengtsson, S Dahlgren, Anders Gummesson, Peter Jacobson, Jan Karlsson, Anna‐Karin Lindroos, Hans Lönroth, Ingmar Näslund, Torsten Olbers, Kaj Stenlöf, Jarl Torgerson, Göran I. Ågren, Lena Carlsson
Discussion(0)
No comments yet. Be the first to comment.